Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11799-11808

  Wang, Yue Dong ^a   Chen, He ^a   Liu, Hui Qiag ^a   Hao, Min ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Osteopontin; Ovarian neoplasm

Indexed keywords

OSTEOPONTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES TUMOR; ASIAN; BLOOD LEVEL; CANCER STAGING; CASE CONTROL STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OVARY TUMOR; PRIORITY JOURNAL; RISK FACTOR; TUMOR VOLUME; BLOOD; OVARIAN NEOPLASMS; PROGNOSIS; PUBLISHING; RISK;

CASE-CONTROL STUDIES; FEMALE; HUMANS; ODDS RATIO; OSTEOPONTIN; OVARIAN NEOPLASMS; PROGNOSIS; PUBLICATION BIAS;

EID: 84925285903     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2314-1     Document Type: Article

References (42)

1. Chambers AF, Vanderhyden BC. Ovarian cancer biomarkers in urine. Clin Cancer Res. 2006;12(2):323–7.
2. Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 2013;51(9):1815–24.
3. Hwang J, Na S, Lee H, Lee D. Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer. J Gynecol Oncol. 2009;20(3):169–75.
4. Koskensalo S, Louhimo J, Nordling S, Hagstrom J, Haglund C. MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol. 2011;32(2):259–64.
5. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol. 2004;93(2):361–5.
6. Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer. 2012;118(21):5210–6.
7. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(21):7677–82.
8. Davidson B, Holth A, Moripen L, Trope CG, Shih IM. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol. 2011;42(7):991–7.
9. Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM, et al. MicroRNA genes and their target 3′-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One. 2012;7(4):e35805.
10. Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, et al. Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol. 2006;23(2):205–12.
11. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23(30):7445–53.
12. Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci. 2007;14(3):373–81.
13. Moszynski R, Szubert S, Szpurek D, Michalak S, Sajdak S. Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res. 2013;39(11):1518–25.
14. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest. 2009;119(6):1583–94.
15. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–13.
16. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3(3–4):311–22.
17. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol. 2009;60(2):225–30.
18. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 2009;4(9):1104–10.
19. Song G, Ouyang G, Mao Y, Ming Y, Bao S, Hu T. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med. 2009;13(8B):1706–18.
20. Lin CK, Chao TK, Lai HC, Lee HS. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. Am J Clin Pathol. 2012;137(6):971–7.
21. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011;9(3):280–93.
22. Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, et al. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol. 2011;90(8):642–8.
23. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res. 2006;32(3):309–14.
24. Fan JB, Zhang GL, Wu J, Gao YE. Clinical value of b-type ultrasonography combined with serum levels of OPN and CA125 in the early diagnosis of ovarian cancer. J Shanxi Med Univ. 2012;43(03):225–8.
25. Li MJ, Yang YQ, Peng CX, Ma XX, Ren R. Significance of OPN combined with CA125 in early diagnosis of ovarian cancer. Progress Mod Biomed. 2013;13(04):691–3.
26. Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
27. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31(29):3805–20.
28. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.
29. Zintzaras E, Ioannidis JP. Hegesma: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.
30. Vrzalova J, Prazakova M, Novotny Z, Topolcan O, Casova M, Holubec Jr L. Test of ovarian cancer multiplex xMAP technology panel. Anticancer Res. 2009;29(2):573–6.
31. Wang Y, Wang J, Zhang ZM, Xie ZY, Guo XX. Clinical significance of serum OPN, HE4 and CA125 levels in patients with ovarian cancer. Progress Mod Biomed. 2013;13(30):5937–40.
32. Wu FJ, Guan S, Huang BY, Wei M. Detection of osteopontin and CA125 in patients with ovarian cancer and its clinical significance. Chin J Lab Diagn. 2009;13(9):1170–2.
33. Xu CL, Wang YH, Lu XL, Wang Y, Chen SQ, Wang HL. Correlation of eukaryotic initiation factor 4E and osteopontin in serum of patients with epithelial ovarian cancer. Progress Obstetrics Gynecol. 2009;18(8):602–4,8.
34. Yan YN, Liu Z, Liu DQ, Li ZT. Combination of serum CA125, HE4 and OPN in the diagnosis of ovarian cancer. Chin J Clin Medicine. 2013;20(04):440–2.
35. Yang B, Jia J, Shi DM, Li J, Chen I. Evaluation of selected serum proteins CA125 and OPN as diagnosis of ovarian cancer. Progress Mod Biomed. 2012;12(9):1742–4.
36. Yang JH, Feng L, Li L, Ma ZM. Diagnosis and prognosis value of the serum OPN, CA125 and CA199 detection in patients with epithelia ovarian cancer. Chin J Family Planning. 2007;146(12):740–2.
37. Zhang YJ, Yuan ZF. Expression and significance of HE4, OPN and c-OPN in carcinoma, ascites, serum and urine in patients with epithelial ovarian cancer. Maternal & Child Health Care China. 2013;28(14):2290–3.
38. Zhou YH, Wu XF. Significance of OPN combined with CA125 in diagnosis of epithelial ovarian cancer. J Clin Exp Med. 2008;07(04):35–7.
39. Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci. 2008;99(10):1901–7.
40. Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 2010;101(8):1828–33.
41. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19(5–6):333–45.
42. Nagasaka A, Matsue H, Matsushima H, Aoki R, Nakamura Y, Kambe N, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol. 2008;38(2):489–99.